Cynomolgus / Rhesus macaque B7-1, His Tag (HPLC-verified) (CD0-C52H3) is expressed from human 293 cells (HEK293). It contains AA Val 35 - Asn 242 (Accession # G7NXN7). In the region Val 35 - Asn 242, the AA sequence of Cynomolgus and Rhesus macaque B7-1 are homologus.
Predicted N-terminus: Val 35
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 25.8 kDa. The protein migrates as 35-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-HPLC.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Cynomolgus / Rhesus macaque B7-1, His Tag (HPLC-verified) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Cynomolgus / Rhesus macaque B7-1, His Tag (HPLC-verified) (Cat. No. CD0-C52H3) was more than 90% as determined by SEC-HPLC.
Immobilized Cynomolgus / Rhesus macaque CTLA-4, Fc Tag (Cat. No. CT4-C5256) at 5 μg/mL (100 μL/well) can bind Cynomolgus / Rhesus macaque B7-1, His Tag (HPLC-verified) (Cat. No. CD0-C52H3) with a linear range of 10-156 ng/mL (QC tested).
Immobilized Human CTLA-4, Fc Tag (Cat. No. CT4-H5255) at 5 μg/mL (100 μL/well) can bind Cynomolgus / Rhesus macaque B7-1, His Tag (HPLC-verified) (Cat. No. CD0-C52H3) with a linear range of 10-156 ng/mL (Routinely tested).
B7-1 and B7-2, together with their receptors CD28 and CTLA4, constitute one of the dominant co-stimulatory pathways that regulate T and Bcell responses. Although both CTLA4 and CD28 can bind to the same ligands, CTLA4 binds to B71 and B72 with a 20 100 fold higher affinity than CD28 and is involved in the downregulation of the immune response. B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.